
Fulcrum Therapeutics Inc
NASDAQ:FULC

Intrinsic Value
The intrinsic value of one
FULC
stock under the Base Case scenario is
2.47
USD.
Compared to the current market price of 7.32 USD,
Fulcrum Therapeutics Inc
is
Overvalued by 66%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Fulcrum Therapeutics Inc
Fundamental Analysis


Revenue & Expenses Breakdown
Fulcrum Therapeutics Inc
Balance Sheet Decomposition
Fulcrum Therapeutics Inc
Current Assets | 249.9m |
Cash & Short-Term Investments | 241m |
Receivables | 3.3m |
Other Current Assets | 5.6m |
Non-Current Assets | 10.8m |
PP&E | 9.6m |
Other Non-Current Assets | 1.2m |
Free Cash Flow Analysis
Fulcrum Therapeutics Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Fulcrum Therapeutics Inc
Revenue
|
80m
USD
|
Operating Expenses
|
-99.8m
USD
|
Operating Income
|
-19.8m
USD
|
Other Expenses
|
10.1m
USD
|
Net Income
|
-9.7m
USD
|
FULC Profitability Score
Profitability Due Diligence
Fulcrum Therapeutics Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

Score
Fulcrum Therapeutics Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
FULC Solvency Score
Solvency Due Diligence
Fulcrum Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Score
Fulcrum Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
FULC Price Targets Summary
Fulcrum Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
FULC
is 7.72 USD
with a low forecast of 2.02 USD and a high forecast of 12.6 USD.
Dividends
Current shareholder yield for FULC is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
FULC
stock under the Base Case scenario is
2.47
USD.
Compared to the current market price of 7.32 USD,
Fulcrum Therapeutics Inc
is
Overvalued by 66%.